Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Interest & Investment Income (2022 - 2026)

Lexeo Therapeutics' Interest & Investment Income history spans 2 years, with the latest figure at $1.1 million for Q4 2023.

  • On a quarterly basis, Interest & Investment Income rose 63.02% to $1.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.9 million, a N/A change, with the full-year FY2025 number at $6.1 million, down 18.87% from a year prior.
  • Interest & Investment Income hit $1.1 million in Q4 2023 for Lexeo Therapeutics, up from $488000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for LXEO hit a ceiling of $1.1 million in Q4 2023 and a floor of $456000.0 in Q3 2022.